An English/Spanish Mobile Augmented Reality Pain Assessment App for Hispanic/Latino Pediatric Cancer Patients
- Conditions
- PainPediatric Cancer
- Interventions
- Device: AR Pain assessment
- Registration Number
- NCT06635434
- Lead Sponsor
- ALTality, Inc.
- Brief Summary
In this SBIR, ALTality, Inc. ("SpellBound") will assess the feasibility of a dual English/Spanish language augmented reality(AR)-enabled tool for assessing inpatient postoperative pain/nausea/vomiting in Hispanic/Latino children and adolescents with cancer in collaboration with bilingual Spanish-speaking anesthesiologists at the MD Anderson Cancer Center. If successful, the AR app will be an immediately implementable and commercially viable method of providing Hispanic/Latino pediatric cancer patients with limited English proficiency an adjunctive tool to overcome infrastructural barriers to receiving translation services in acute care settings that put them at higher risk of under and/or overtreatment of pain by prescription opioids and future prescription opioid dependency and misuse, at no cost to them or their families.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 16
- ages 7-17 years old
- child able to provide assent, and a legal guardian able to provide informed consent
- current diagnosis of pediatric cancer
- undergoing surgery for cancer treatment requiring postoperative inpatient hospitalization
- prescribed or expected to be prescribed opioids during inpatient perioperative period
- sufficient mental capacity to comprehend and interact with the game in English or Spanish.
- the inability to play with the SpellBound app from English or Spanish instructions
- daily opioid use within 30 days prior to surgery
- any concerns from the treatment team.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Augmented reality-enabled pain assessment deployed on a mobile AR Pain assessment Age-stratified (age 7-11 and age 12-17 years old) augmented reality app to evaluate for pain and opioid-related adverse events with equivalent English and Spanish text, audio, and narration
- Primary Outcome Measures
Name Time Method Primary; Percent of enrolled patients who activated/used the app during the PACU stay immediately after the intervention/procedure/surgery Feasibility measured as activation/usage of the app recorded by the device ID for each patient
- Secondary Outcome Measures
Name Time Method Total time spent playing on the AR app during the PACU stay immediately after the intervention/procedure/surgery Length of time (minutes) of app usage recorded by the device ID for each patient
Recorded responses about pain assessment from the app immediately after the intervention/procedure/surgery Pain scale score in English or Spanish through the app
Recorded responses about nausea/vomit assessment from the app immediately after the intervention/procedure/surgery Baxter animated retching scale score in English or Spanish through the app
Inpatient opioid consumption immediately after the intervention/procedure/surgery Calculated as morphine equivalent dose of all opioids given
Length of stay immediately after the intervention/procedure/surgery Total time (minutes) spent in the PACU after surgery
Quality of life survey immediately after the intervention/procedure/surgery PedsQL survey administered to child and/or adult caregiver stratified by age
Rate of opioid prescription immediately after the intervention/procedure/surgery The percentage of patients with opioid prescriptions at the time of discharge from the electronic health record
Patient/caregiver satisfaction survey immediately after the intervention/procedure/surgery Asked to the patient/caregiver by the study team - 1) How satisfied were you with regards to your pain management in PACU?, 2) How satisfied were you with regards to your nausea management in PACU?, 3) How satisfied were you with the use of the AR app to help assess your pain and nausea?
Trial Locations
- Locations (1)
MD Anderson Cancer Center
🇺🇸Houston, Texas, United States